A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

Abstract Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1–5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27–74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1–26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

[1]  A. Ferreri,et al.  Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. , 2015, The oncologist.

[2]  B. Cho,et al.  Public Perceptions on Cancer Incidence and Survival: A Nation-wide Survey in Korea , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[3]  T. Nakazato,et al.  A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study , 2015, International Journal of Hematology.

[4]  F. Cavalli,et al.  Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group , 2014, British journal of haematology.

[5]  Yoonjin Cho,et al.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.

[6]  J. Tuscano,et al.  Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.

[7]  W. Au,et al.  A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma , 2014, British journal of haematology.

[8]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[9]  M. Mayerhoefer,et al.  Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) , 2014, Annals of Hematology.

[10]  A. Stathis,et al.  The management of nongastric MALT lymphomas. , 2014, Oncology.

[11]  S. Schuster,et al.  Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas , 2014, Cancer.

[12]  A. Amiot,et al.  Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study , 2013, Leukemia & lymphoma.

[13]  N. Schmitz,et al.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jinny Park,et al.  Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study , 2012, Annals of Hematology.

[15]  W. Kim,et al.  WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study , 2011 .

[16]  Dae-Ho Lee,et al.  Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial , 2010, Investigational New Drugs.

[17]  P. Innominato,et al.  Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  I. Sobhani,et al.  Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up , 2010, Leukemia & lymphoma.

[19]  Jinny Park,et al.  Relapsed or refractory nongastric marginal zone B‐cell lymphoma: Multicenter retrospective analysis of 92 cases , 2009, American journal of hematology.

[20]  Dae-Ho Lee,et al.  A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma , 2009, Cancer Chemotherapy and Pharmacology.

[21]  E. Zucca,et al.  Marginal-zone lymphoma. , 2007, Critical reviews in oncology/hematology.

[22]  Max Wolf,et al.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.

[23]  U. Jaeger,et al.  Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Keunchil Park,et al.  Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases , 2007, American journal of hematology.

[25]  A. Bleyer,et al.  Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma , 2005, Cancer.

[26]  P. Isaacson.  Update on MALT lymphomas. , 2005, Best practice & research. Clinical haematology.

[27]  S. Pileri,et al.  Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma , 2005, Leukemia & lymphoma.

[28]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[29]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Simon,et al.  How large should a phase II trial of a new drug be? , 1987, Cancer treatment reports.